PRA Health Sciences, Inc. (PRAH): Price and Financial Metrics


PRA Health Sciences, Inc. (PRAH): $165.21

-2.80 (-1.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PRAH POWR Grades


  • Growth is the dimension where PRAH ranks best; there it ranks ahead of 99.25% of US stocks.
  • PRAH's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • PRAH ranks lowest in Sentiment; there it ranks in the 17th percentile.

PRAH Stock Summary

  • With a market capitalization of $10,704,848,034, PRA Health Sciences Inc has a greater market value than 81.66% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for PRAH is 2.14 -- better than 76.89% of US stocks.
  • With a price/earnings ratio of 50.18, PRA Health Sciences Inc P/E ratio is greater than that of about 80.43% of stocks in our set with positive earnings.
  • If you're looking for stocks that are quantitatively similar to PRA Health Sciences Inc, a group of peers worth examining would be RXN, KTOS, FFIV, TECH, and G.
  • Visit PRAH's SEC page to see the company's official filings. To visit the company's web site, go to prahs.com.

PRAH Valuation Summary

  • PRAH's price/earnings ratio is 51.4; this is 48.99% higher than that of the median Healthcare stock.
  • Over the past 81 months, PRAH's price/earnings ratio has gone up 72.7.
  • Over the past 81 months, PRAH's price/earnings ratio has gone up 72.7.

Below are key valuation metrics over time for PRAH.

Stock Date P/S P/B P/E EV/EBIT
PRAH 2019-08-08 2.2 5.5 40.6 25.7
PRAH 2019-03-08 2.3 6.4 43.4 27.3
PRAH 2018-03-06 2.4 5.8 62.1 54.2
PRAH 2016-02-19 1.7 3.5 -67.7 86.6
PRAH 2015-07-21 1.6 3.7 -66.2 84.9
PRAH 2015-02-27 1.2 3.9 -34.1 280.8

PRAH Price Target

For more insight on analysts targets of PRAH, see our PRAH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $167.75 Average Broker Recommendation 1.95 (Hold)

PRAH Stock Price Chart Interactive Chart >

Price chart for PRAH

PRAH Price/Volume Stats

Current price $165.21 52-week high $175.95
Prev. close $168.01 52-week low $93.00
Day low $164.28 Volume 13,411,000
Day high $168.76 Avg. volume 837,472
50-day MA $169.23 Dividend yield N/A
200-day MA $135.82 Market Cap 10.70B

PRA Health Sciences, Inc. (PRAH) Company Bio


PRA Health Sciences provides various product development services for pharmaceutical and biotechnology companies worldwide. The company was founded in 1976 and is based in Raleigh, North Carolina.

PRAH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$165.21$197.31 13%

We started the process of determining a valid price forecast for PRA Health Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that PRA Health Sciences Inc ranked in the 57th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of PRA Health Sciences Inc, consider:

  • PRAH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 33.46% of tickers in our DCF set.
  • As a business, PRA Health Sciences Inc experienced a tax rate of about 17% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 73.91% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%11%
1%12%
2%13%
3%14%
4%16%
5%17%

JAZZ, ESMC, PNTG, OMI, and BIO can be thought of as valuation peers to PRAH, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


PRAH Latest News Stream


Event/Time News Detail
Loading, please wait...

PRAH Latest Social Stream


Loading social stream, please wait...

View Full PRAH Social Stream

Latest PRAH News From Around the Web

Below are the latest news stories about PRA Health Sciences Inc that investors may wish to consider to help them evaluate PRAH as an investment opportunity.

Robert W. Baird Stick to Their Hold Rating for PRA Health Sciences By Investing.com

Robert W. Baird Stick to Their Hold Rating for PRA Health Sciences

Investing.com | June 29, 2021

Should I Buy PRA Health Sciences Inc (PRAH)?

No summary available.

Insider Monkey | June 29, 2021

DT Midstream Set to Join S&P MidCap 400

DT Midstream Inc. (NYSE: DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE: DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500.

Yahoo | June 28, 2021

Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research

Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.

Yahoo | June 25, 2021

Veradigm and PRA Health Sciences Partner to Create the Industry’s Leading EHR-Based Clinical Research Network

CHICAGO, June 23, 2021--Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), and PRA Health Sciences, Inc. (NASDAQ: PRAH), one of the world’s leading global contract research organizations, announced today the creation of the industry’s leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States.

Yahoo | June 23, 2021

Read More 'PRAH' Stories Here

PRAH Price Returns

1-mo N/A
3-mo -2.99%
6-mo 35.56%
1-year 54.94%
3-year 57.03%
5-year 234.30%
YTD 31.70%
2020 12.86%
2019 20.87%
2018 0.98%
2017 65.22%
2016 21.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9242 seconds.